Anti-Osteoprotegerin antibody [bony-1]
Be the first to review this product! Submit a review
|
(1 Publication)
Rat Monoclonal Osteoprotegerin antibody. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human TNFRSF11B aa 1-250.
View Alternative Names
OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin
- Flow Cyt
Unknown
Flow Cytometry - Anti-Osteoprotegerin antibody [bony-1] (AB18051)
FACS analysis of cells with ab18051.
HEK 293T cells (5 x 105) were mock transfected (thin line) or transfected with an expression plasmid enabling surface expression of the TNFR homology domain of human OPG (thick line). Cells were incubated on ice for 30 min in 50μl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide)
containing 1μg/ml of ab18051. After washing in FACS buffer, R-PE-conjugated antibody to rat IgG was added. Cells were incubated on ice for 30 min, washed and then analyzed by Flow Cytometry.
Reactivity data
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.
Pathways
OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Scientific reports 11:23649 PubMed34880328
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com